Cart
sales@molnova.com
GSK-LSD1 dihydrochloride
CAS No. 1431368-48-7
GSK-LSD1 dihydrochloride ( —— )
Catalog No. M17295 CAS No. 1431368-48-7
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | In Stock |
|
| 5MG | 72 | In Stock |
|
| 10MG | 115 | In Stock |
|
| 25MG | 241 | In Stock |
|
| 50MG | 366 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK-LSD1 dihydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
DescriptionGSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorLSD1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1431368-48-7
-
Formula Weight289.24
-
Molecular FormulaC14H22Cl2N2
-
Purity98%
-
Solubility——
-
SMILESc1ccc(cc1)[C@@H]1C[C@H]1NC1CCNCC1.Cl.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Structural Genomics Consortium.
molnova catalog
related products
-
Pyrotinib
Pyrotinib (SHR-1258)is a potent and selective EGFR/HER2 dual inhibitor with IC50 of 13/38 nM, respectively.
-
TX1-85-1
TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
-
Genistein
Genistein(NPI 031L), a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM.
